Cisplatin remains a cornerstone in the treatment of various solid tumors, including ovarian, testicular, and lung cancers. However, its therapeutic utility is severely restricted by its significant nephrotoxic profile, which often results in Cisplatin-induced acute kidney injury. This clinical complication affects approximately one-third of patients receiving high-dose chemotherapy, leading to increased morbidity and potential treatment discontinuation. Researchers have long sought pharmacological interventions to mitigate this damage without compromising the antineoplastic efficacy of the drug. Sulforaphane, a bioactive isothiocyanate found abundantly in cruciferous vegetables like broccoli, has emerged as a compelling candidate for nephroprotection. By serving as a potent agonist of the nuclear factor erythroid 2-related factor 2 (NRF2) pathway, Sulforaphane demonstrates remarkable antioxidant and anti-inflammatory properties. Recent experimental data suggest that Sulforaphane significantly attenuates renal dysfunction by orchestrating a robust cellular defense mechanism. This article explores the underlying molecular pathways through which Sulforaphane exerts its protective effects, focusing on its ability to inhibit oxidative stress and apoptosis in the renal tubular environment. Understanding these mechanisms is vital for clinicians aiming to improve patient outcomes during intensive chemotherapy regimens.

The Clinical Challenge of Cisplatin-induced Acute Kidney Injury

The development of Cisplatin-induced acute kidney injury represents a major hurdle in clinical oncology. This condition typically manifests as a rapid decline in glomerular filtration rate, accompanied by an elevation in serum creatinine and blood urea nitrogen levels. Furthermore, cisplatin accumulates preferentially in the proximal convoluted tubules, where it reaches concentrations significantly higher than those in the blood. Consequently, this selective accumulation triggers a series of pathological events, including mitochondrial dysfunction and vascular damage within the renal parenchyma. Clinicians often observe that current preventive strategies, such as aggressive hydration and forced diuresis, provide only partial protection. Therefore, there is an urgent need for targeted molecular therapies that can directly safeguard renal cells from cisplatin-mediated toxicity. The psychological and physical burden on patients experiencing renal failure during cancer treatment is substantial, often necessitating dose reductions or the complete cessation of life-saving chemotherapy. Moreover, survivors of acute kidney injury are at a heightened risk for developing chronic kidney disease later in life. This long-term risk underscores the importance of identifying effective renoprotective agents. Sulforaphane represents a promising avenue for research due to its well-documented safety profile and its systemic ability to enhance the body's endogenous detoxification systems.

Oxidative Stress and the Inflammatory Cascade

The pathogenesis of renal injury following cisplatin administration is multifactorial, involving a complex interplay between oxidative stress and inflammatory signaling. Specifically, cisplatin induces the excessive production of reactive oxygen species (ROS) within renal tubular epithelial cells. These highly reactive molecules cause lipid peroxidation, damage cellular proteins, and induce DNA strand breaks. Additionally, the drug depletes essential intracellular antioxidants such as glutathione and superoxide dismutase, further sensitizing the kidneys to oxidative damage. This redox imbalance subsequently activates the inflammatory response, characterized by the infiltration of macrophages and the release of pro-inflammatory cytokines. Markers such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) play a pivotal role in amplifying the initial injury. Importantly, the persistent inflammatory milieu promotes cellular apoptosis via the activation of caspase-3 and Bax proteins. As a result, the renal tubules undergo extensive structural damage, leading to the shedding of epithelial cells into the tubular lumen and the formation of casts. By targeting these specific pathways, therapeutic agents can potentially interrupt the cycle of damage. Recent studies indicate that suppressing these inflammatory markers is essential for preserving renal architecture and function. Sulforaphane specifically addresses these issues by modulating the cellular redox status and dampening the cytokine storm associated with cisplatin exposure.

Sulforaphane as a Potent Activator of the NRF2 Signaling Pathway

The primary mechanism behind the nephroprotective effect of Sulforaphane is its ability to regulate the NRF2 signaling pathway. NRF2 is a master transcription factor that governs the expression of over 200 cytoprotective genes involved in antioxidant defense and detoxification. Under normal physiological conditions, NRF2 remains sequestered in the cytoplasm by its inhibitor, KEAP1. However, Sulforaphane facilitates the dissociation of NRF2 from KEAP1, allowing it to translocate into the nucleus. Once in the nucleus, NRF2 binds to the antioxidant response elements (ARE) in the promoter regions of target genes. This binding subsequently upregulates the synthesis of phase II detoxifying enzymes and antioxidant proteins. Furthermore, Sulforaphane-mediated NRF2 activation effectively restores the balance between pro-oxidant and antioxidant systems in the kidney. Evidence suggests that SFN not only increases the levels of heme oxygenase-1 (HO-1) but also enhances the availability of reduced glutathione. This systemic boost in antioxidant capacity allows renal cells to neutralize cisplatin-generated ROS before they can inflict irreversible damage. Additionally, NRF2 activation has been shown to cross-talk with anti-apoptotic pathways, providing a multi-layered shield for the renal tubular epithelium. This molecular regulation highlights Sulforaphane as a highly sophisticated agent capable of addressing the root causes of chemotherapy-related nephrotoxicity.

Experimental Findings: In Vivo and In Vitro Nephroprotection

Extensive research using both animal models and cell culture systems has validated the efficacy of Sulforaphane. In vivo studies involving C57BL/6 mice demonstrated that Sulforaphane treatment significantly lowered serum levels of creatinine and blood urea nitrogen following a cisplatin challenge. Notably, histological examinations revealed that Sulforaphane preserved the tubular architecture and reduced the presence of periodic acid-Schiff-positive lesions. Similarly, biochemical analysis showed a marked reduction in renal injury markers such as kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL). In vitro experiments using HK-2 human proximal tubule cells further confirmed these findings. When researchers treated these cells with Sulforaphane prior to cisplatin exposure, they observed a significant increase in cell viability and a reduction in the rate of apoptosis. Furthermore, the use of the NRF2 inhibitor ML385 partially reversed the protective effects of Sulforaphane, proving that the NRF2 pathway is indispensable for its action. These results collectively indicate that Sulforaphane provides a robust defense against cisplatin-induced cellular death. The consistency of these findings across different models strengthens the case for Sulforaphane as a therapeutic candidate. Moreover, the study highlighted that Sulforaphane effectively inhibited the activation of caspase-3, which is the final executioner of the apoptotic pathway in damaged renal tissues.

Therapeutic Implications for Oncological Care

The potential clinical application of Sulforaphane in oncology extends beyond mere nephroprotection. By mitigating the side effects of cisplatin, Sulforaphane may allow clinicians to maintain higher and more effective doses of chemotherapy. Consequently, this could lead to improved tumor response rates and better overall survival for cancer patients. Furthermore, Sulforaphane is a naturally occurring compound with a favorable toxicity profile, making it an attractive adjunctive therapy. Future clinical trials are necessary to determine the optimal dosage and timing of Sulforaphane administration in humans. However, the current preclinical evidence provides a strong foundation for such investigations. Importantly, Sulforaphane does not appear to interfere with the anti-tumor activity of cisplatin, which is a critical requirement for any protective agent used in oncology. Therefore, it may serve as a safe and effective strategy for managing chemotherapy-associated kidney injury in a variety of clinical settings. As precision medicine continues to evolve, the integration of bioactive compounds like Sulforaphane into standard care protocols represents a holistic approach to patient health. This research emphasizes the importance of continuing to explore the synergistic relationship between nutrition, pharmacology, and oncology to optimize the therapeutic index of established chemotherapeutic agents.

Frequently Asked Questions

How does Sulforaphane specifically activate the NRF2 pathway in renal cells?

Sulforaphane functions as an electrophile that modifies specific cysteine residues on the KEAP1 protein. This modification disrupts the interaction between KEAP1 and NRF2, preventing the degradation of the transcription factor. Consequently, NRF2 accumulates and translocates into the nucleus, where it initiates the transcription of various antioxidant and cytoprotective genes. This process effectively bolsters the endogenous defense systems of the kidney against external chemical stressors like cisplatin.

What are the primary biomarkers reduced by Sulforaphane in the context of AKI?

Research indicates that Sulforaphane significantly reduces classic markers of renal dysfunction, including serum creatinine and blood urea nitrogen. Furthermore, it downregulates highly specific renal injury markers such as kidney injury molecule-1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL). These reductions correlate with improved histological findings, such as decreased tubular necrosis and preserved brush border integrity, demonstrating the comprehensive nature of Sulforaphane's protective effects on the renal parenchyma.

Can Sulforaphane be used alongside chemotherapy in human patients currently?

While preclinical studies show immense promise, Sulforaphane is currently considered an experimental adjunctive therapy rather than a standard of care. Patients should consult their oncologists before incorporating Sulforaphane supplements, as clinical trials are still establishing the definitive human dosage and safety parameters. However, the existing data suggest that Sulforaphane provides significant nephroprotection without compromising the cancer-killing efficacy of cisplatin, making it a major focus of ongoing clinical research.

Disclaimer: This content is for informational and educational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. Refer to the latest local and national guidelines for clinical practice.

References

Wu Z et al. Sulforaphane attenuates cisplatin‑induced acute kidney injury by inhibiting oxidative stress, inflammation and apoptosis via regulation of NRF2. Mol Med Rep. 2026 Aug undefined. doi: undefined. PMID: 42359648.

Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations. PMC10214631.

Activation of the Nrf2 Pathway by Sulforaphane Improves Hypoglycaemia-Induced Cognitive Impairment in a Rodent Model of Type 1 Diabetes. PMC11130620.